ClinicalTrials.gg
RecruitingNCT06068491Vet-CALDUpdated Nov 13, 2026

Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)

An interventional study of Vet-CALD in Liver Diseases, sponsored by VA Office of Research and Development. Recruiting at 8 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 13, 2026Results publication addedSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 369 studies in Liver Diseases with a site in United States — 46 open to participants now, 60 under way, 5 of them phase 3. Liver Diseases · United States.

Planned enrollment
16th of 270
450 · median 48
Started
2024
with 19 others
No phase
87 of 369
7 open now
Primary completion
2027-09
later than 22 of 58 live
Registered
323rd of 369
by date

Among the 369 studies in Liver Diseases with a site in United States, this one is the 16th largest by planned enrollment of the 270 interventional ones that give a count, is one of 20 that started in 2024, is one of 87 with no phase, reaches primary completion later than 22 of the 58 other live ones, and was the 323rd registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

46 of the 369 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 105 Liver Diseases studies recruiting now, 52 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

Advanced liver disease is a serious illness that disproportionately affects Veterans, many of whom hope for curative liver transplantation. However, too few receive a transplant and most continue to suffer from increasing symptoms and hospitalizations. The proposed project uses a whole person, Veteran-centered approach that identifies Veterans with advanced liver disease using a population-based health management system and integrates curative and early supportive care using a telemedicine-based nurse care counselor to (1) discuss patient's understanding of illness severity and prognosis, (2) identify priorities and care preferences and (3) align curative and supportive care options to achieve patient priorities. Study outcomes include changes in (1) rates of consideration for liver transplantation, and (2) completion of serious illness discussions. Findings will inform adaptations to the intervention and facilitators for its dissemination.

Read the detailed description

Project Background and Rationale: Advanced liver disease (AdvLD) is a serious illness. As many as half of AdvLD patients die within 2 years of developing liver complications, and nearly all suffer increasing symptoms and hospitalizations. Although many patients hope for curative liver transplantation, few receive it while experiencing an increasingly severe illness. In previous studies, many patients with AdvLD reported unmet curative and supportive care needs. They also reported preferences to align care with their outcome goals earlier in the AdvLD course than is now common. The Vet-CALD program is a Whole Health program in AdvLD that focuses on what matters most to patients, shared goals, and goal-aligned treatments, and could improve both curative and supportive care.

Project Objectives: The overall goal of the Vet-CALD project is to develop and test a novel sustainable Whole Health program in caring for patients with AdvLD. Using a hybrid type 1 effectiveness-implementation study design, the project will: (Aim 1) conduct a formative assessment of Vet-CALD implementation for Veterans with AdvLD; (Aim 2) evaluate the effectiveness of Vet-CALD in a randomized controlled study at 8 VA centers; and (Aim 3) conduct a summative assessment of implementation outcomes.

Project Methods: In Aim 1, the study team will conduct in-depth qualitative interviews with clinical stakeholders and patients to identify steps necessary to refine the Vet-CALD intervention, develop engagement processes for patients, and establish integrated workflows at the four targeted VA sites.

In Aim 2 the study team will conduct a randomized clinical trial (N=450) with patients from 8 VA medical centers assigned (1:1) to Usual Care vs. Vet-CALD Intervention. The Vet-CALD intervention will consist of a centralized research care counselor who will work with individual patients by telehealth (3 to 5 visits over 6 months) to assess and cultivate their understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized care team (hepatologist and supportive care physician) and will work with each patient's usual providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.

In Aim 3, Summative assessment will provide context for the effectiveness results and inform necessary adaptations to and dissemination of Vet-CALD.

03

Conditions studied

  • Liver Diseases

Browse trials for

Keywords

  • Patient-Centered Care
  • Randomized Controlled Trial
  • Delivery of Healthcare, Integrated
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be Veterans
  • Patients must have been in care at one of the recruiting sites with 1 or more encounters in primary care or GI/Hepatology in the last 24 months
  • Patients must have advanced liver disease, defined by ICD-10 codes for cirrhosis complications (ever) or MELD 3.0 >=12 or MELD-Na >=12 or Fibroscan LSM >20 kilopascal (kpa)

Exclusion criteria

Exclusion Criteria:

  • Non-Veteran patients
  • Patients who do not speak English, do not have access to a telephone or computers, have cognitive impairments, or who are unable to complete a valid form after three attempts
  • Patients who have already made significant progress toward our endpoints: a) with prior history of liver transplantation, or b) on the liver transplant waiting list, or c) had formal evaluation for liver transplantation in the past 3 years
  • Patients with very limited (advanced cancer, acute-on-chronic liver failure, and hospice patients)
  • Patients hospitalized, or in long term facilities or nursing homes at the time they meet inclusion criteria
  • Patients with chart diagnosis of uncontrolled mental health or schizophrenia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Arm 1: Vet-CALD Intervention

    Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.

    Other: Vet-CALD

  • No intervention
    Arm 2: Usual Care

    Usual Care Participants will receive the standard of care from their usual VA healthcare provider. The care counselor will not contact the usual care condition participants.

Interventions

  • OtherVet-CALD

    Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.

06

What researchers measure

Primary outcomes

  1. Electronic Health Record (EHR) documentation of consideration for liver transplantation change

    Consideration of Liver Transplantation will be measured dichotomously by assigning a value of 1 if the patient's EHR includes at least one clinician note that documents consideration of liver transplantation as a potential treatment option for the patient within 6 months and 12 months of enrollment, and a value of 0 otherwise.

    Time frame: 6 and 12 months

  2. Electronic Health Record (EHR) documentation of goals of care conversation change

    Goals of Care Conversation will be measured dichotomously by assigning a value of 1 if the patient's EHR includes at least one clinician note documenting discussion of goals of care planning within 6 months and 12 months of enrollment, and a value of 0 otherwise.

    Time frame: 6 and 12 months

Secondary outcomes

  1. Receipt of goal concordant care

    Receipt of Goal Concordant Care will be measured using a 2-item survey. The first question defines patient preferences for either extending life or ensuring comfort. The second question assesses patients' perceptions of their current treatment with the same choices. The outcome is a dichotomous variable measuring whether preferences matched the patient's report of current care.

    Time frame: 6 months

  2. Health Related Quality of Life (HRQoL)

    HRQoL will be measured at baseline and 6-months using the 10-item Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 instrument, which measures general domains of health including physical function, emotional distress, social health, as well as perceptions of general health that cut across domains, plus fatigue and pain. PROMIS-10 items are scored from 1 to 5 (Poor to Excellent; Not at All to Completely; Always to Never; Very Severe to None) and averaged to provide a mean HRQoL score ranging from 1 to 5. (T-score, higher score indicates better HRQoL.).

    Time frame: 6 months

  3. Perceived quality of shared decision-making

    Perceived shared decision making will be measured using the 3-item CollaboRATE scale (scored 0 to 9; possible range 0-100; = 0.89 higher score indicates greater perceived shared decision-making and goal ascertainment)

    Time frame: 6 months

  4. Satisfaction with care

    Satisfaction with Care will be measured using the 4-item Satisfaction with Care - Feeling Heard and Understood survey. (scored 0-4; Not at All True to Completely True; possible range 0-16; higher score indicates greater satisfaction with care and goal ascertainment).

    Time frame: 6 months

  5. Quality of symptomatic advanced liver disease (AdvLD) care

    Quality of symptomatic care will be measured using a broad measure of quality based on selected AASLD's process-based quality indicators (QIs). Adherence to a given QI will be scored as 1 with evidence for satisfying the indicator. Quality of care at the patient level will be calculated by dividing the number of QIs for which that individual received the indicated care by the number of QIs for which the individual is eligible for during the 12-month follow up time.

    Time frame: 12 months

07

Study locations

7 of 8 sites recruiting
08

References and documents

Publications

  • Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670. Epub 2023 Nov 9. PubMed 38445559 ↗
  • Belliveau O, Mezzacappa C, Patel A, Kapo J, Kaplan D, Taddei T. Predictors and Outcomes of Palliative Care Consultation in Veterans Hospitalized with Alcohol-Associated Hepatitis. J Palliat Med. 2026 Sep 22:10966218261488082. doi: 10.1177/10966218261488082. Online ahead of print. PubMed 42773632 ↗

Individual participant data

Plan to share: Yes — Data sharing will be accomplished through manuscript publications and presentations at scientific conferences. Requests for Limited Datasets (LDS) will be considered with appropriate data use agreements (DUAs) and IRB approvals. The investigators will remove all HIPAA identifiers before sharing datasets. DUAs will limit use of the dataset and prohibit the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: starting 6 months after publication

Access criteria: Aggregate data will be shared through manuscripts, reports and conference presentations. Corresponding Limited Data Sets (LDS) shared will include all the variables contained within our datasets (except for the 18 HIPAA identifiers). This will allow validation of our results by the recipients. Requests may be submitted to Fasiha Kanwal, MD, the overall PI, starting 6 months after publication and up to 4 years after the study ends.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

Of 122 non-industry interventional studies with no phase under Liver Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's planned 35 months is above that.

Counting every sponsor, half of 135 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Sep 2027, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Oct 5, 2023
StartActual
Oct 1, 2024
Primary completionEst.
Sep 30, 2027was Sep 2026
CompletionEst.
Sep 30, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • VA Long Beach Healthcare System, Long Beach, CA · Long Beach, United StatesNot yet recruiting→Recruiting
  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT · West Haven, United StatesNot yet recruiting→Recruiting
  • Miami VA Healthcare System, Miami, FL · Miami, United StatesNot yet recruiting→Recruiting
Nov 13, 2026
Primary completion
Sep 30, 2026→Sep 30, 2027
Nov 13, 2026
Eligibility
1 inclusion criterion edited, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedPatients will be between 18 and 80 years of age
  • EditedPatients must have advanced liver disease, defined by ICD-10 codes for cirrhosis complications (ever) or MELD 3.0 >=12 or MELD-Na >=12 or Fibroscan LSM >20kpa20 kilopascal (kpa)
Nov 13, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedElectronic Health Record (EHR) documentation of consideration for liver transplantation changeTime frame: 6 and 12 months
  • EditedElectronic Health Record (EHR) documentation of goals of care conversation changeTime frame: 6 and 12 months
Nov 13, 2026
Publications
Results publication added: Belliveau O, Mezzacappa C, Patel A, Kapo J, Kaplan D, Taddei T. Predictors and Outcomes of Palliative Care Consultation in Veterans Hospitalized with Alcohol-A… PubMed 42773632 ↗
Nov 13, 2026
Contact
Study contact's phone or email changed: none listed→•••4400. See the current contact
Nov 13, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • VA Long Beach Healthcare System, Long Beach, CA · Long Beach, United StatesContact D•••@va.gov · •••4423→j•••@va.gov · •••4466
  • VA Greater Los Angeles Healthcare System, West Los Angeles, CA · West Los Angeles, United StatesContact F•••@va.gov · •••4495→F•••@va.gov · •••4495Contact added (no phone or email listed)Contact added (no phone or email listed)
  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT · West Haven, United StatesContact D•••@va.gov · •••4423→j•••@va.gov · •••4466
  • Miami VA Healthcare System, Miami, FL · Miami, United StatesContact D•••@va.gov · •••4423→j•••@va.govContact F•••@va.gov · •••4495→F•••@va.gov · •••4495Contact added (no phone or email listed)
  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX · Dallas, United StatesContact F•••@va.gov · •••4495→F•••@va.gov · •••4495Contact added (no phone or email listed)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Publications Results publication added: Belliveau O, Mezzacappa C, Patel A, Kapo J, Kaplan D, Taddei T. Predictors and Outcomes of Palliative Care Consultation in Veterans Hospitalized with Alcohol-A… PubMed 42773632 ↗
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • VA Long Beach Healthcare System, Long Beach, CA · Long Beach, United StatesNot yet recruiting→Recruiting
    • VA Connecticut Healthcare System West Haven Campus, West Haven, CT · West Haven, United StatesNot yet recruiting→Recruiting
    • Miami VA Healthcare System, Miami, FL · Miami, United StatesNot yet recruiting→Recruiting
    Primary completion Sep 30, 2026→Sep 30, 2027
    Eligibility 1 inclusion criterion edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedPatients will be between 18 and 80 years of age
    • EditedPatients must have advanced liver disease, defined by ICD-10 codes for cirrhosis complications (ever) or MELD 3.0 >=12 or MELD-Na >=12 or Fibroscan LSM >20kpa20 kilopascal (kpa)
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedElectronic Health Record (EHR) documentation of consideration for liver transplantation changeTime frame: 6 and 12 months
    • EditedElectronic Health Record (EHR) documentation of goals of care conversation changeTime frame: 6 and 12 months
    Contact Study contact's phone or email changed: none listed→•••4400. See the current contact
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • VA Long Beach Healthcare System, Long Beach, CA · Long Beach, United StatesContact D•••@va.gov · •••4423→j•••@va.gov · •••4466
    • VA Greater Los Angeles Healthcare System, West Los Angeles, CA · West Los Angeles, United StatesContact F•••@va.gov · •••4495→F•••@va.gov · •••4495Contact added (no phone or email listed)Contact added (no phone or email listed)
    • VA Connecticut Healthcare System West Haven Campus, West Haven, CT · West Haven, United StatesContact D•••@va.gov · •••4423→j•••@va.gov · •••4466
    • Miami VA Healthcare System, Miami, FL · Miami, United StatesContact D•••@va.gov · •••4423→j•••@va.govContact F•••@va.gov · •••4495→F•••@va.gov · •••4495Contact added (no phone or email listed)
    • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX · Dallas, United StatesContact F•••@va.gov · •••4495→F•••@va.gov · •••4495Contact added (no phone or email listed)
    + 3 other changes: identifiers, verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06068491
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Oct 1, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Juana Campos, MA
Contact
juana.campos@va.gov
(713) 440-4400
Fasiha Kanwal, MD MSHS
Contact
Fasiha.Kanwal@va.gov
(713) 440-4495
Fasiha Kanwal, MD MSHS
principal investigator · Michael E. DeBakey VA Medical Center, Houston, TX
Anne M Walling, MD PhD
principal investigator · VA Greater Los Angeles Healthcare System, West Los Angeles, CA
Steven M. Asch, MD MPH
principal investigator · VA Palo Alto Health Care System, Palo Alto, CA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion